Clinical trial

Days Alive and Out of Hospital for Patients With Sepsis

Name

DAOHsepsis140920

Description

We will perform a retrospective cohort study to assess the construct validity and performance of days alive and out of hospital at day 90 (DAOH90) in cohorts of patients with sepsis and septic shock who have been included in recent clinical trials.

Trial arms

Trial start

2020-09-14

Estimated PCD

2024-02-23

Trial end

2024-02-23

Status

Completed

Treatment

Hydroxyethyl starch

Hydroxyethyl starch compared to 0.9% saline

Arms:

CHEST Study

Hydrocortisone

Hydrocortisone compared to Placebo

Arms:

ADRENAL study

Early Goal Directed Therapy

Early Goal Directed Therapy compared to Usual Care

Arms:

ARISE Study

Size

6213

Primary endpoint

Quality of Life as measured by the EQ5D

6 months

Eligibility criteria

Inclusion Criteria: * We will include data from all participants in the ARISE and ADRENAL trials where there is data available to calculate the number of days alive and out of hospital to Day 90, and data available with regards to quality of life at 6 months following recruitment. * We will include data from all participants in the CHEST trial who had a diagnosis of sepsis at baseline, and for whom there is data available to calculate the number of days alive and out of hospital to Day 90 and data available with regards to quality of life at 6 months following recruitment

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 6213, 'type': 'ACTUAL'}}

Updated at

2024-02-23

1 organization

2 products

2 indications

Organization

The George Institute for Global Health

Product

Indication

Indication

Product